Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial

AIMS: Chronic kidney disease (CKD) challenges diabetes management and is associated with increased cardiovascular morbidity and mortality. We examined whether clinical outcomes with insulin glargine 300 U/mL (Gla‐300) and insulin degludec 100 U/mL (IDeg‐100) are affected by renal function in a presp...

Descripción completa

Detalles Bibliográficos
Autores principales: Haluzík, Martin, Cheng, Alice, Müller‐Wieland, Dirk, Westerbacka, Jukka, Bosnyak, Zsolt, Lauand, Felipe, Melas‐Melt, Lydie, Karalliedde, Janaka, Rosenstock, Julio, Bolli, Geremia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383874/
https://www.ncbi.nlm.nih.gov/pubmed/32243043
http://dx.doi.org/10.1111/dom.14043

Ejemplares similares

Ejemplares similares